Quentis, an immuno-oncology therapy developer based on research at Weill Cornell Medicine, has closed a round that included Taiho Pharmaceuticals and AbbVie Ventures.
Quentis Therapeutics, US-based immuno-oncology drug developer based on research at Cornell University, has closed a $48m series A round featuring pharmaceutical companies AbbVie and Taiho, the former investing through its AbbVie Ventures unit.
Venture capital firm Versant Ventures and investment firm Polaris Partners co-led the round along with LS Polaris Innovation Fund, an affiliate of the latter.
The round also featured Alexandria Venture Investments and New York Ventures, respective investment vehicles for real estate investment trust Alexandria Real…
